Use

The Rapid AML Therapeutic Panel identifies genetic abnormalities associated with acute myeloid leukemia (AML) that are useful for risk stratification and therapeutic decision making. This panel utilizes a combination of bi‑directional Sanger sequencing, PCR and FISH with a fast turnaround time. AML is usually an in‑patient hematologic diagnosis and prompt time to treatment assignment can improve patient outcomes significantly.